logo

QNCX

Quince Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.59 / 10
Netural

QNCX's fundamental assessment is challenging, rated 3.6/10. Key positives include a favorable PB-ROE and Profit-MV, but significant negatives are a low Gross Profit Margin and weak Revenue-MV. The stock underperforms on asset turnover and profitability ratios, indicating operational inefficiencies and limited financial strength. Overall, the company lacks robust fundamental underpinnings, which constrains its investment appeal.

Fundamental(3.59)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.26
Score1/3
Weight10.55%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight9.27%
1M Return5.26%
Gross profit margin (%)
Value36.70
Score1/3
Weight-0.81%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight15.80%
1M Return7.79%
PB-ROE
Value-0.66
Score3/3
Weight24.81%
1M Return11.47%
Current assets turnover ratio
Value1.78
Score2/3
Weight1.85%
1M Return1.15%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.35%
1M Return0.86%
Asset-MV
Value-0.50
Score1/3
Weight19.15%
1M Return8.74%
Cash-MV
Value-0.07
Score2/3
Weight15.82%
1M Return7.73%
Net profit / Total profit (%)
Value100.15
Score2/3
Weight2.23%
1M Return1.28%
Is QNCX fundamentally strong?
  • QNCX scores 3.59/10 on fundamentals and holds a Fair valuation at present. Backed by its -285.35% ROE, 0.00% net margin, -0.16 P/E ratio, 7.31 P/B ratio, and 3.23% earnings growth, these metrics solidify its Netural investment rating.